Abstract
We investigated the impact of antiviral treatment on the emergence of SARS-CoV-2 resistance during persistent infections in immunocompromised patients (n=15). All patients received remdesivir and some also received nirmatrelvir-ritonavir or monoclonal antibodies. Sequence analysis showed that nine patients carried viruses with mutations in the nsp12 (RNA dependent RNA polymerase), while four had viruses with nsp5 (3C protease) mutations. Infectious SARS-CoV-2 with a double mutation in nsp5 (T169I) and nsp12 (V792I) was recovered from respiratory secretions 77 days after initial COVID-19 diagnosis from a patient treated with remdesivir and nirmatrelvir-ritonavir. In vitro characterization confirmed its decreased sensitivity to remdesivir and nirmatrelvir, which was overcome by combined antiviral treatment. Studies in golden Syrian hamsters demonstrated efficient transmission to contact animals. This study documents the isolation of SARS-CoV-2 carrying resistance mutations to both nirmatrelvir and remdesivir from a patient and demonstrates its transmissibility in vivo.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Sequencing was performed in part by the New York Genome Center (NYGC) Sequencing Laboratory as part of the COVID-19 Genomic Research Network (CGRN) with funds generously provided by NYGC donors and the JPB Foundation. This work was funded in part by the National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID) grant no. R01AI166791-01 (to D.G.D), by the Division of Intramural Research of the NIAID/NIH (E.G.), by the Office of Vice President for Research at Cornell University and the Office of the Dean for Research and Graduate Education at the College of Veterinary Medicine at Cornell University (D.G.D) and by the Weill Cornell Medicine National Center for Advancing Translational Science of the National Institute of Health (award number UL1TR002384).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Weill Cornell Medicine gave ethical approval for this work (IRB 20-03021645)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵# Senior authors
